These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 6540986)

  • 1. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon.
    Ettinger WH; Wise RA; Schaffhauser D; Wigley FM
    Am J Med; 1984 Sep; 77(3):451-6. PubMed ID: 6540986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A thromboxane synthetase inhibitor in Raynaud's phenomenon.
    Jones EW; Hawkey CJ
    Prostaglandins Leukot Med; 1983 Sep; 12(1):67-71. PubMed ID: 6356154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation.
    Malamet R; Wise RA; Ettinger WH; Wigley FM
    Am J Med; 1985 Apr; 78(4):602-8. PubMed ID: 3157318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dazoxiben, a thromboxane synthetase inhibitor on skin-blood flow following cold challenge in patients with Raynaud's phenomenon.
    Tindall H; Tooke JE; Menys VC; Martin MF; Davies JA
    Eur J Clin Invest; 1985 Feb; 15(1):20-3. PubMed ID: 3921380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of thromboxane synthetase inhibition in Raynaud's phenomenon.
    Coffman JD; Rasmussen HM
    Clin Pharmacol Ther; 1984 Sep; 36(3):369-73. PubMed ID: 6467796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial.
    Belch JJ; Cormie J; Newman P; McLaren M; Barbenel J; Capell H; Leiberman P; Forbes CD; Prentice CR
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):113S-116S. PubMed ID: 6337601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon.
    Corbin DO; Wood DA; Macintyre CC; Housley E
    Eur Heart J; 1986 Feb; 7(2):165-70. PubMed ID: 3516704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium channel blockers for primary Raynaud's phenomenon.
    Ennis H; Hughes M; Anderson ME; Wilkinson J; Herrick AL
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD002069. PubMed ID: 26914257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium channel blockers for primary Raynaud's phenomenon.
    Ennis H; Anderson ME; Wilkinson J; Herrick AL
    Cochrane Database Syst Rev; 2014 Jan; (1):CD002069. PubMed ID: 24482037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon.
    Luderer JR; Nicholas GG; Neumyer MM; Riley DL; Vary JE; Garcia G; Schneck DW
    Clin Pharmacol Ther; 1984 Jul; 36(1):105-15. PubMed ID: 6428793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome.
    Rustin MH; Grimes SM; Kovacs IB; Cooke ED; Bowcock SA; Sowemimo-Coker SO; Turner P; Kirby JD
    Eur J Clin Pharmacol; 1984; 27(1):61-5. PubMed ID: 6386490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon.
    Gjørup T; Kelbaek H; Hartling OJ; Nielsen SL
    Am Heart J; 1986 Apr; 111(4):742-5. PubMed ID: 3513504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Raynaud's phenomenon with calcium channel blockers.
    Smith CR; Rodeheffer RJ
    Am J Med; 1985 Feb; 78(2B):39-42. PubMed ID: 3976694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon.
    Smith CD; McKendry RJ
    Lancet; 1982 Dec; 2(8311):1299-301. PubMed ID: 6128596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon.
    Gjørup T; Hartling OJ; Kelbaek H; Nielsen SL
    Eur J Clin Pharmacol; 1986; 31(4):387-9. PubMed ID: 3816916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood viscosity, finger systolic pressure and effect of dazoxiben treatment in primary vasospastic disease.
    Sandhagen B; Wegener T; Hägg A
    Ups J Med Sci; 1984; 89(3):213-9. PubMed ID: 6393521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Objective benefit of nifedipine in the treatment of Raynaud's phenomenon. Double-blind controlled study.
    White CJ; Phillips WA; Abrahams LA; Watson TD; Singleton PT
    Am J Med; 1986 Apr; 80(4):623-5. PubMed ID: 3515931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial.
    Sauza J; Kraus A; González-Amaro R; Alarcón-Segovia D
    J Rheumatol; 1984 Jun; 11(3):362-4. PubMed ID: 6376801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenon.
    Creager MA; Pariser KM; Winston EM; Rasmussen HM; Miller KB; Coffman JD
    Am Heart J; 1984 Aug; 108(2):370-3. PubMed ID: 6380254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.